Cargando…

Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer

OBJECTIVE: Lung cancer is a major cause of cancer-related deaths and thus represents a global health problem. According to World Health Organization (WHO) estimates, approximately 1.37 million people die each year from lung cancer. Different therapeutic approaches as well as several treatment option...

Descripción completa

Detalles Bibliográficos
Autores principales: Mühlbacher, Axel C., Bethge, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464047/
https://www.ncbi.nlm.nih.gov/pubmed/25135768
http://dx.doi.org/10.1007/s10198-014-0622-4
_version_ 1782375880831533056
author Mühlbacher, Axel C.
Bethge, Susanne
author_facet Mühlbacher, Axel C.
Bethge, Susanne
author_sort Mühlbacher, Axel C.
collection PubMed
description OBJECTIVE: Lung cancer is a major cause of cancer-related deaths and thus represents a global health problem. According to World Health Organization (WHO) estimates, approximately 1.37 million people die each year from lung cancer. Different therapeutic approaches as well as several treatment options exist. To date decisions on which therapies to use have largely been made by clinical experts. Comparative preference studies show that underlying weighting of treatment goals by experts is not necessarily congruent with the preferences of affected patients. AIM AND METHODS: The aim of this empirical study was to ascertain patient preferences in relation to treatment of non-small-cell lung cancer (NSCLC). After identification of patient-relevant treatment attributes via literature review and qualitative interviews(ten) a discrete-choice experiment including seven patient-relevant attributes was conducted using a fractional factorial NGene-design. Statistical data analysis was performed using latent class models. RESULTS: The qualitative part of this study identified outcome measures related to efficacy, side effects and mode of administration. A total of 211 NSCLC patients (N = 211) participated in the computer-assisted personal interview. A clear preference for an increase in “progression-free survival” (coef.: 1.087) and a reduction of “tumor-associated symptoms”(cough, shortness of breath and pain); coef.: 1.090) was demonstrated, followed by the reduction of side effects: “nausea and vomiting” (coef.: 0.605); “rash” (coef.: 0.432); “diarrhea” (coef.: 0.427); and, “tiredness and fatigue” (coef.: 0.423). The “mode of administration” was less important for participants (coef.: 0.141). CONCLUSION: Preference measurement showed “progression-free survival” and “tumor-associated symptoms” had a significant influence on the treatment decision. Subgroup analysis revealed that the importance of “progression-free survival” increases with increased therapy experience. Based on the presented results therapies can be designed, assessed and chosen on the basis of patient-oriented findings. As such, more effective and efficient care of patients can be achieved and benefits increased.
format Online
Article
Text
id pubmed-4464047
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-44640472015-06-17 Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer Mühlbacher, Axel C. Bethge, Susanne Eur J Health Econ Original Paper OBJECTIVE: Lung cancer is a major cause of cancer-related deaths and thus represents a global health problem. According to World Health Organization (WHO) estimates, approximately 1.37 million people die each year from lung cancer. Different therapeutic approaches as well as several treatment options exist. To date decisions on which therapies to use have largely been made by clinical experts. Comparative preference studies show that underlying weighting of treatment goals by experts is not necessarily congruent with the preferences of affected patients. AIM AND METHODS: The aim of this empirical study was to ascertain patient preferences in relation to treatment of non-small-cell lung cancer (NSCLC). After identification of patient-relevant treatment attributes via literature review and qualitative interviews(ten) a discrete-choice experiment including seven patient-relevant attributes was conducted using a fractional factorial NGene-design. Statistical data analysis was performed using latent class models. RESULTS: The qualitative part of this study identified outcome measures related to efficacy, side effects and mode of administration. A total of 211 NSCLC patients (N = 211) participated in the computer-assisted personal interview. A clear preference for an increase in “progression-free survival” (coef.: 1.087) and a reduction of “tumor-associated symptoms”(cough, shortness of breath and pain); coef.: 1.090) was demonstrated, followed by the reduction of side effects: “nausea and vomiting” (coef.: 0.605); “rash” (coef.: 0.432); “diarrhea” (coef.: 0.427); and, “tiredness and fatigue” (coef.: 0.423). The “mode of administration” was less important for participants (coef.: 0.141). CONCLUSION: Preference measurement showed “progression-free survival” and “tumor-associated symptoms” had a significant influence on the treatment decision. Subgroup analysis revealed that the importance of “progression-free survival” increases with increased therapy experience. Based on the presented results therapies can be designed, assessed and chosen on the basis of patient-oriented findings. As such, more effective and efficient care of patients can be achieved and benefits increased. Springer Berlin Heidelberg 2014-08-19 2015 /pmc/articles/PMC4464047/ /pubmed/25135768 http://dx.doi.org/10.1007/s10198-014-0622-4 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Paper
Mühlbacher, Axel C.
Bethge, Susanne
Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer
title Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer
title_full Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer
title_fullStr Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer
title_full_unstemmed Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer
title_short Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer
title_sort patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464047/
https://www.ncbi.nlm.nih.gov/pubmed/25135768
http://dx.doi.org/10.1007/s10198-014-0622-4
work_keys_str_mv AT muhlbacheraxelc patientspreferencesadiscretechoiceexperimentfortreatmentofnonsmallcelllungcancer
AT bethgesusanne patientspreferencesadiscretechoiceexperimentfortreatmentofnonsmallcelllungcancer